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Introduction
Post-kala-azar dermal leishmaniasis
(PKDL) is a macular, papular, and/or
nodular skin rash that can appear as a
sequel of visceral leishmaniasis (VL)
caused by Leishmania donovani. In Bangla-
desh, it occurs in around 10% of VL
patients, leading to high prevalences of 6/
10,000–21/10,000 population in endemic
regions [1,2]. Over 95% of lesions are
macular and cause no or little physical
discomfort to patients. However, Leishman-
ia parasites can been found in PKDL
lesions, and there is (sparse) evidence that
they are infective to sandflies [3,4,5]. It is
generally assumed that PKDL patients
form an infectious reservoir and should be
treated in order to achieve disease control.
There are no evidence-based treatments
for PKDL. Therefore, treatment can be
considered experimental, and treatment
choices are ‘‘best guesses’’ based on good
results in small clinical studies and clinical
experience in the field.
Me´decins Sans Frontie`res provides
treatment for VL and PKDL in Fulbaria,
a highly endemic subdistrict of Mymen-
singh in Bangladesh. Active case finding is
undertaken, and free-of-charge short-
course treatment with liposomal ampho-
tericin B (L-AMB) (AmBisome, Gilead,
United States) is provided for both VL and
PKDL. L-AMB was designated by the
World Health Organization (WHO) as the
safest and most effective treatment for VL
in the Indian subcontinent [6]. The
optimal treatment for PKDL has not been
established by clinical trials. Based on the
safety and efficacy of L-AMB given in high
total cumulative doses (50–90 mg/kg) for
treatment of PKDL in small patient
cohorts in East Africa [7,8], a regimen
was chosen with a total cumulative dose of
30 mg/kg, divided into six doses of 5 mg/
kg L-AMB, given over a period of 3 weeks
on an ambulatory basis. This dose and
frequency were chosen to minimise the
impact on patients’ daily lives. L-AMB is
known to be a safe treatment for VL in
similar doses [9]. It was expected that L-
AMB in this dose regimen would cause
minimal adverse effects in otherwise
healthy PKDL patients.
PKDL was diagnosed by clinical eval-
uation of lesions. More than 1,300 PKDL
patients have been treated to date. Unex-
pectedly, we encountered hypokalaemia-
induced rhabdomyolysis during or follow-
ing treatment. Here, we present six
confirmed cases and one presumed case
of this rare adverse event that occurred in
the period from October to December of
2011. After three cases of confirmed
rhabdomyolysis, further enrolment of
PKDL patients was stopped. Patients still
under treatment were closely monitored
for the occurrence of hypokalaemia.
Presentation of Cases
Case 1. An 18-year-old female returned
to the clinic 2 days after her fifth dose of L-
AMB, unable to walk, sit up unaided, or
even hold her head up due to severe muscle
pain and weakness, predominantly in the
proximal muscles. We were unable to
perform biochemical assays. The patient
improved gradually, and her symptoms
resolved completely.
Case 2. An 11-year-old girl presented
with a rapid onset of severe muscle pain
and weakness in upper and lower
extremities 3 days after her sixth dose of
L-AMB. Serum creatinine phosphokinase
(CPK) was .18,000 U/L, confirming
rhabdomyolysis. Serum potassium levels
were not obtained. The girl was treated
with IV fluids and oral potassium
supplements (potassium-rich foods), and
she improved spontaneously over the next
few days with a complete recovery
recorded after 4 weeks.
Case 3. An 18-year-old male developed
muscle weakness and pain a few days after
receiving his sixth dose of L-AMB. Serum
CPK was 11,764 U/L and serum K+ was
1.7 mmol/L. Urine dipstick assay was
strongly positive for haemoglobin but
negative for red blood cells, suggesting
myoglobinuria. The patient received oral
K+ supplementation and IV fluids and
improved quickly with a complete
resolution of symptoms within 1 week.
Case 4. Two days after her sixth dose of
L-AMB, an 11-year-old girl developed
severe muscle pain, weakness, arthralgia,
nausea, and vomiting. Sensory examination
was normal, but tendon reflexes in lower
extremities were weak or absent. Investiga-
tions revealed serum CPK 12,703 U/L, K+
1.7 mmol/L, and creatinine 0.5 mg/dL,
suggesting rhabdomyolysis with concurrent
hypokalaemia. Urine was discoloured
(brown), and dipstick urine analysis was
positive for haemoglobin, but urine micros-
copy was negative for red blood cells,
suggesting myoglobinuria. The patient
received IV fluids and oral K+
supplementation and improved with a
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complete resolution of symptoms within 4
weeks.
Case 5. A 17-year-old female develop-
ed severe muscle pain and weakness 1 day
after her sixth dose of L-AMB. She was able
to walk supported but could not sit up after
lying down or stand up after sitting down.
There was obvious muscle tenderness and a
loss of tendon reflexes in upper and lower
limbs. Serum CPK was 16,505 U/L, K+
1.9 mmol/L and creatinine 0.6 mg/dL,
suggesting rhabdomyolysis. Discoloured
(brown) urine in which dipstick assay was
positive for haemoglobin but urine
microscopy negative for red blood cells
suggested myoglobinuria. The patient
received oral K+ supplementation and IV
fluids and recovered fully within 2 weeks.
Case 6. A 13-year-old girl developed
hypokalaemia (serum K+ 2.6 mmol/l) at
her sixth dose of L-AMB. Urine dipstick
was positive for haemoglobin but urine
microscopy negative for red cells, suggesting
myoglobinuria. Upon questioning, she
admitted experiencing muscle pain, nausea,
and vomiting. On examination, there was
obvious muscle tenderness. She received oral
K+ supplementation and IV fluids. Her
serum CPK obtained 3 days after start of
K+ supplementation was 2,233 U/l and
creatinine 0.5 mg/dl. Her symptoms
resolved completely within 2 weeks.
Case 7. A 13-year-old female gradually
developed moderate hypokalaemia, with a
nadir serumK+ of 2.8 mmol/L, 1 week after
receiving her sixth dose of L-AMB. On
examination, there was muscle tenderness in
thighs and muscle pain on exertion. Serum
CPK rose from 140 U/L at this point to
2,548 U/L 1 week later. Serum creatinine
remained 0.5–0.6 mg/dL. She received K+
supplementation from her fourth dose of L-
AMB on, and her symptoms resolved
completely one week after onset.
All seven patients were followed up with
history, clinical examination, and testing
of serum CPK, K+, Na+, creatinine, urea,
liver enzymes, and urine dipstick 2–4
months later. These revealed no relevant
pathology, and in all cases, CPK returned
to normal levels, and symptoms complete-
ly resolved.
Case Discussions
Six cases of confirmed and one pre-
sumed case of clinical rhabdomyolysis
post-PKDL treatment with L-AMB
30 mg/kg were diagnosed over a period
of 3 months. Three patients had rhabdo-
myolysis accompanying severe hypokalae-
mia (serum K+,2.5 mmol/L), and in two
further cases, hypokalaemia was moderate
(2.5–3.0 mmol/L), although it is possible
that the lowest K+ levels were not
recorded. Notably, in both these cases,
hypokalaemia occurred a few days before
serum CPK was significantly elevated.
Five of six were females aged 11–17 years.
Apart from PKDL, none had any signif-
icant comorbidity, concomitant use of
drugs, or other cofactors. Positivity of
urine haemoglobin assay was considered
to be due to myoglobinuria, supported by
the concomitant elevation of CPK and
absence of red blood cells in urine.
Haemolysis was not suspected, and there
were no clinical signs of anaemia. Hae-
moglobin levels in blood were not ob-
tained.
A retrospective search was done for
symptoms consistent with rhabdomyolysis
in the records of all PKDL patients
(n = 1,292) who had received L-AMB,
and it found a further 19 patients with
symptoms consistent with rhabdomyolysis.
Among these 19 patients diagnosed in
retrospect, 18 were female and 15 aged
11–26 years. No patients ,11 years old
developed rhabdomyolysis. In all cases,
there was a clear temporal relationship
between onset of the myalgia or muscle
weakness and treatment with L-AMB and
between the resolution of symptoms and
ending L-AMB. No indication was found
that another diagnosis or another drug was
implicated in either the seven directly
observed cases above or among the 19
possible cases of rhabdomyolysis that were
diagnosed retrospectively. Pharmacovigi-
lance analysis of the patient files by the
Geneva University Hospital considered a
causal link to the L-AMB treatment
probable in 23 and possible in three of
the 26 of the PKDL patients. PKDL
patients are not thought to have disease
of the muscles or of any organ system
other than the skin. L-AMB was devel-
oped primarily to reduce nephrotoxicity
commonly seen with conventional ampho-
tericin B deoxycholate (c-AMB). Com-
pared to c-AMB, L-AMB has a greatly
improved safety profile [10]; the encapsu-
lation of amphotericin B in liposomes
leads to decreased glomerular filtration
and an altered distribution with low
plasma levels of free amphotericin B,
increasing its efficacy and significantly
reducing nephrotoxicity [11,12].
Both nephrotoxicity and hypokalaemia
are dose-dependent adverse reactions to L-
AMB treatment [13,14]. Hypokalaemia is
commonly seen after both c-AMB and L-
AMB administration; however, it is less
frequent with L-AMB [10,15]. In three
large trials establishing safety and toler-
ance of L-AMB, hypokalaemia was seen
in 22–43% of patients treated with
3–15 mg/kg/day of L-AMB for up to 83
days (maximum cumulative dose 972 mg/
kg) [10,15–17]. Severe hypokalaemia ,
2.5 mmol/L was reported in one study,
affecting 7% of patients treated with
3 mg/kg/day for a mean of 1169 days.
Overall, severe hypokalaemia is rare, but it
is reasonable to assume that study partic-
ipants received potassium supplementa-
tion when necessary.
Hypokalaemia-induced rhabdomyolysis
caused by c-AMB has been seldom
reported and only in paediatric patients
[18]. The true incidence of post-L-AMB
rhabdomyolysis is unknown. Rhabdomy-
olysis was not a known side effect of L-
AMB until it was occasionally reported in
post–marketing surveillance and remained
very rare: in 21 years of experience, only
8–9 cases have been reported from Japan
(incidence 1:100,000) (verbal communica-
tion, Gilead). In 2012, rhabdomyolysis was
approved by the US Food and Drug
Administration (FDA) for inclusion as an
infrequent adverse effect in the AmBisome
package insert. The FDA reports accessed
through FDA Freedom of Information
Department reveal 27 unique cases of
rhabdomyolysis after AmBisome, includ-
ing 14 of the cases reported in this paper
above. However, no details were shared,
and diagnoses may be uncertain. In
principle, medical professionals are re-
quired to report all adverse events related
to a licensed drug. In practice, this is
seldom done; moreover, it is at the
discretion of the professional to decide
whether an adverse event is related to the
drug. Hypokalaemia-induced rhabdomy-
olysis can prove challenging to diagnose,
as muscle lysis will lead to an immediate
and often significant increase in serum
potassium levels, masking the aetiology.
Moreover, one can argue mild cases of
rhabdomyolysis may go unnoticed in the
severely ill, bed-bound patients with fungal
infections who are the typical recipients of
L-AMB (as opposed to our otherwise
healthy patient group).
A possible explanation for unexpected
adverse events with a well-known drug is a
drug-quality problem; this was excluded
by reanalysis of a sample of L-AMB by
Gilead. One vial of unreconstituted AmBi-
some from the batch used in the clinic at
the time when the above cases were
treated was randomly selected and trans-
ported, in temperatures below 25uC, to
Gilead’s laboratory in the US. The sterile
water and 5% dextrose solution used for
reconstitution and infusion of AmBisome
had both undergone thorough testing
before the start of the program, and the
same manufacturer was employed
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throughout the program. Exposure of L-
AMB to temperatures over 30uC will
increase its toxicity because the liposomes
will start to deteriorate and release free
amphotericin B. The Me´decins Sans
Frontie`res (MSF) team in Dhaka has
confirmed that storage and transport were
carried out in temperatures below 25uC.
Temperatures are recorded at all times,
and recording devices’ logs were double-
checked.
Hypokalaemia is a well-established
cause of muscle-cell necrosis and rhabdo-
myolysis. However, it is not clear why our
patients reacted with such severe hypoka-
laemia to L-AMB treatment. It is possible
that the events are related to the use of L-
AMB in a chronically malnourished pop-
ulation. However, apart from clinical
studies, safety data from routine use of L-
AMB in resource-limited settings is very
limited, as no systematic post-marketing
pharmacovigilance surveillance has been
done in Asia and Africa, except in India,
where MSF implemented L-AMB for VL
in a total dose of 20 mg/kg, administered
as 5 mg/kg doses on days 0, 1, 4, and 9.
No serious side effects were observed in a
cohort of 2,510 patients [19], apart from a
non-life-threatening swelling of the lips.
However, electrolytes and creatinine were
not routinely measured. In our patients,
toxicity generally occurred at the fifth or
sixth dose of L-AMB (25 mg/kg total dose
and 30 mg/kg total dose, respectively),
suggesting a cumulative effect. It should be
noted that in 20 clinical trials of L-AMB in
VL a total of 2,293 individuals have
received total doses of 3.75–76 mg per
kg and daily doses of 1–15 mg per kg; no
cases of rhabdomyolysis and no cases of
serum K+ ,2 mmol/L were reported
[19–38]. Mild hypokalaemia was rarely
reported but not actively monitored in all
trials.
Among our patients with rhabdomyol-
ysis, six of seven were adolescent girls, a
pattern that is also seen among the
possible cases diagnosed in retrospect.
Why this group is more susceptible than
others is unclear. Micronutrient deficiency
might provide an explanation and has
been found among adolescent girls in
Bangladesh in several studies [39–42].
Magnesium deficiency aggravates hypoka-
laemia, which often becomes refractory to
treatment. Amphotericin B, also in liposo-
mal form, induces magnesium wasting
[17,43], further worsening a possible
deficiency. It has been suggested that the
high prevalence of eclampsia among
young Bangladeshi women is explained
by high rates of magnesium deficiency
[44].
Because PKDL in Bangladesh is a non-
life-threatening condition that generally
does not cause physical impairment and
because treatment is mainly provided for
public health reasons, the risk/benefit
ratio of treatment for individual PKDL
patients needs to be extremely low, using a
very safe treatment. Because of the
observed occurrence of life-threatening
side effects, a 30 mg/kg total dose
L-AMB regimen is not recommended as
routine treatment for PKDL in Bangla-
desh. Further research on the effectiveness
and safety of a lower dose L-AMB regimen
is currently planned in order to establish
an effective, safe, and acceptable treat-
ment for PKDL that does not require strict
clinical and laboratory monitoring and
that can be adopted in the National Kala
Azar Elimination Programme in Bangla-
desh. Until more is known about the safety
of L-AMB in this particular setting, it may
be advisable to monitor serum potassium
levels in patients receiving L-AMB in
cumulative doses of 20 mg/kg or more.
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